Scientific information remains useful only when its source, methods, population and limitations stay attached to the reported result.
This was an early pharmacology study, not an outcomes trial
A 2006 publication reported two randomized, placebo-controlled, double-blind ascending-dose studies of CJC-1295 in healthy adults aged 21 to 61 years. The studies lasted 28 and 49 days and focused on pharmacokinetic measures and changes in growth hormone and insulin-like growth factor I (IGF-I).
That design is useful for asking whether a defined investigational intervention changes measured biomarkers under controlled conditions. It does not test a clinical endpoint, a disease-specific benefit or long-term outcomes.
Evidence should become more specific as a claim becomes more consequential.
The endpoints were concentrations and duration
The investigators reported sustained, dose-dependent changes in circulating growth hormone and IGF-I after the trial intervention, together with an estimated half-life. These are pharmacodynamic and pharmacokinetic observations: they describe what was measured in a specific trial formulation, schedule and healthy-volunteer population.
A biomarker change is not interchangeable with a clinical outcome. When reading an early-phase report, keep the measured molecule, sampling period and study population attached to the conclusion.
- Link to the original source.
- Name the study design and population.
- Report the observed endpoint factually.
- Disclose important limitations.
- Never convert trial reporting into a product recommendation.
Healthy-volunteer findings have a narrow scope
The short studies were not designed to establish benefit for a medical condition, long-term safety, or outcomes in a patient population. Their sample and follow-up also cannot answer questions about a different formulation, material source or handling history.
This summary does not provide a protocol, dose, route or recommendation. EternaGen research products are not represented as clinical interventions or as suitable for human or veterinary use.
Primary references
These sources were checked against the linked publisher, regulator or literature-index record on 21 July 2026.
